021-51111890
购物车（）
sales@molnova.cn
ORY-1001
CAS No. 1431304-21-0
ORY-1001 ( Ladademstat | RG-6016 )
产品货号. M11826 CAS No. 1431304-21-0
ORY-1001 (RG-6016, Ladademstat) 是一种高效、选择性的赖氨酸特异性去甲基酶 KDM1A (LSD1) 抑制剂，IC50 为 18 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 25MG | ￥9858 | 有现货 |
|
| 50MG | ￥12834 | 有现货 |
|
| 100MG | ￥15750 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称ORY-1001
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述ORY-1001 (RG-6016, Ladademstat) 是一种高效、选择性的赖氨酸特异性去甲基酶 KDM1A (LSD1) 抑制剂，IC50 为 18 nM。
-
产品描述ORY-1001 (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases; exhibits low nanomolar cellular activity (EC50 < 1 nM) in the THP1 differentiation assay and induces the CD11b marker within 6 hr of treatment in FACS based differentiation assay in THP1 cell line; induces H3K4me2 accumulation on KDM1A target genes, blast differentiation, and reduction of leukemic stem cell capacity in AML; exhibits potent synergy with standard-of-care drugs and selective epigenetic inhibitors, reduces growth of AML xenograft models.Blood Cancer Phase 2 Clinical.
-
体外实验——
-
体内实验——
-
同义词Ladademstat | RG-6016
-
通路Chromatin/Epigenetic
-
靶点Histone Demethylase
-
受体Histone Demethylase
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number1431304-21-0
-
分子量286.375
-
分子式C17H22N2O2
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESC1CC(CCC1N)NC2CC2C3=CC=CC=C3
-
化学全称(1r,4R)-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Maes T, et al. Cancer Cell. 2018 Mar 12;33(3):495-511.e12.
